3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
8
Polycystic Ovary Syndrome
3
Peripheral Nervous System Diseases
2
Obesity
2
Neoplasms
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Triple Negative Breast Neoplasms
1
Tracheal Diseases
1
TP53 Y220C Mutation
1
Squamous Cell Carcinoma of Head and Neck
1
Smoking
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic Neoplasms
1
Overweight
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Multiple Myeloma
1
Motor Activity
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Interventions
Doxorubicin
6
Specimen Handling
5
Radiotherapy
3
Radiation
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Biopsy
3
pembrolizumab
2
liposomal doxorubicin
2
eribulin
2
Ifosfamide
2
Dacarbazine
2
toripalimab
1
talimogene laherparepvec
1
rucaparib
1
ribociclib
1
regorafenib
1
peposertib
1
pazopanib
1
olaratumab
1
olaparib
1
lenvatinib
1
futibatinib
1
durvalumab
1
dinutuximab
1
cemiplimab
1
cediranib
1
cabozantinib
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leiomyosarcoma
×
Tablets
×
1 year
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled